Tianjin Pharmaceutical Da Ren Tang Group Notes Planned Sale of Upstream Shareholder

SGX Filings

May 19

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on May, 19 2026 that its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (TPH), has been informed of a proposed transfer of 100% of the equity in Shanghai Liuliguang Medical Development Co., Ltd.

\n\n

SIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. intend to sell their entire stakes in Liuliguang Medical through a public tender on the Shanghai United Assets and Equity Exchange. The pre-disclosure period for the tender runs from May, 19 2026 to Jun, 16 2026.

\n\n

Liuliguang Medical holds 35% of Jinhushen Biological Medical Science and Technology Co., Ltd., which owns 67% of TPH. TPH directly controls approximately 43.008% of Tianjin Pharmaceutical Da Ren Tang Group’s issued share capital. The tender details have been posted on the exchange’s website.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1108253605"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108253605\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108253605?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108253605","market":"sg","top_or_hot":-1,"title":"Tianjin Pharmaceutical Da Ren Tang Group Notes Planned Sale of Upstream Shareholder","media":"SGX Filings","content":"<p>Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on May, 19 2026 that its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (TPH), has been informed of a proposed transfer of 100% of the equity in Shanghai Liuliguang Medical Development Co., Ltd.</p>\n<p>\\n\\n</p>\n<p>SIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. intend to sell their entire stakes in Liuliguang Medical through a public tender on the Shanghai United Assets and Equity Exchange. The pre-disclosure period for the tender runs from May, 19 2026 to Jun, 16 2026.</p>\n<p>\\n\\n</p>\n<p>Liuliguang Medical holds 35% of Jinhushen Biological Medical Science and Technology Co., Ltd., which owns 67% of TPH. TPH directly controls approximately 43.008% of Tianjin Pharmaceutical Da Ren Tang Group’s issued share capital. The tender details have been posted on the exchange’s website.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Pharmaceutical Da Ren Tang Group Notes Planned Sale of Upstream Shareholder</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Pharmaceutical Da Ren Tang Group Notes Planned Sale of Upstream Shareholder\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2026-05-19 23:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on May, 19 2026 that its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (TPH), has been informed of a proposed transfer of 100% of the equity in Shanghai Liuliguang Medical Development Co., Ltd.</p>\n<p>\\n\\n</p>\n<p>SIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. intend to sell their entire stakes in Liuliguang Medical through a public tender on the Shanghai United Assets and Equity Exchange. The pre-disclosure period for the tender runs from May, 19 2026 to Jun, 16 2026.</p>\n<p>\\n\\n</p>\n<p>Liuliguang Medical holds 35% of Jinhushen Biological Medical Science and Technology Co., Ltd., which owns 67% of TPH. TPH directly controls approximately 43.008% of Tianjin Pharmaceutical Da Ren Tang Group’s issued share capital. The tender details have been posted on the exchange’s website.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"T14.SI","symbol_name":"达仁堂","start_time":0,"source_url":"","article_id":"1108253605","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108253605","pubTimestamp":1779203573,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on May, 19 2026 that its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (TPH), has been informed of a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"T14.SI":"达仁堂"},"translate_title":"天津制药达仁堂集团注意到上游股东的计划出售","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"T14.SI":1},"content_text":"Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited announced on May, 19 2026 that its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (TPH), has been informed of a proposed transfer of 100% of the equity in Shanghai Liuliguang Medical Development Co., Ltd.\n\\n\\n\nSIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. intend to sell their entire stakes in Liuliguang Medical through a public tender on the Shanghai United Assets and Equity Exchange. The pre-disclosure period for the tender runs from May, 19 2026 to Jun, 16 2026.\n\\n\\n\nLiuliguang Medical holds 35% of Jinhushen Biological Medical Science and Technology Co., Ltd., which owns 67% of TPH. TPH directly controls approximately 43.008% of Tianjin Pharmaceutical Da Ren Tang Group’s issued share capital. The tender details have been posted on the exchange’s website.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}